NeoGenomics (NEO)
(Delayed Data from NSDQ)
$17.17 USD
-0.33 (-1.89%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $17.19 +0.02 (0.12%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth A Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
NEO 17.17 -0.33(-1.89%)
Will NEO be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for NEO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NEO
Here's What Key Metrics Tell Us About NeoGenomics (NEO) Q2 Earnings
Here's What Key Metrics Tell Us About NeoGenomics (NEO) Q1 Earnings
NEO: What are Zacks experts saying now?
Zacks Private Portfolio Services
NeoGenomics (NEO) Reports Q1 Loss, Tops Revenue Estimates
Will Myriad Genetics (MYGN) Report Negative Q1 Earnings? What You Should Know
NeoGenomics (NEO) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Other News for NEO
Analysts Offer Insights on Healthcare Companies: American Well (AMWL), United Therapeutics (UTHR) and NeoGenomics (NEO)
NeoGenomics (NEO) Gets a Hold from Morgan Stanley
NeoGenomics Outperforms with Strong Q2 and Growth Potential: Analyst Ups Price Target to $30
Why Merck Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
What You Missed On Wall Street This Morning